CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
If implemented across the world, it has the capability to save over 100,000 lives annually
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Subscribe To Our Newsletter & Stay Updated
